CAR-T Cells Targeting Autoimmune Diseases

Recruiting now · Phase 1/Phase 2

Conditions studied: Autoimmune Diseases

In brief

The purpose of this study is to assess the feasibility, safety and efficacy of CAR-T cell therapy in patients with autoimmune disease. Another goal of the study is to learn more about the safety and function of the CAR-T cells and their persistency in autoimmune disease patients.

Key facts

Study ID

NCT05459870

Run by

Shenzhen Geno-Immune Medical Institute

People needed

30

Starts

2026-06-01

Expected to finish

2030-12-31

Last updated by the study team

2026-06-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age older than 18 years.
• expression of B cell surface molecules.
• the KPS score over 80 points, and survival time is more than 3 months.
• greater than Hgb 80 g/L.
• no contraindications to blood cell collection.

You may not qualify if…

• accompanied with other active diseases and difficult to assess treatment response.
• bacterial, fungal, or viral infection, unable to control.
• living with HIV.
• active HBV or HCV infection.
• pregnant and nursing mothers.
• under systemic steroid treatment within a week of the treatment.
• prior failed CAR-T treatment.

Where it is running

• Shenzhen Geno-immune Medical Institute — Shenzhen, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.